Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Global Spotlight: The Most Cost-Effective Countries for Cataract Surgery
Cataract surgery remains one of the most common and effective ophthalmic procedures globally, but the cost can be a significant barrier for many patients. In an increasingly interconnected world, medical tourism has emerged as a viable solution, offering high-quality, affordable…
Sandoz and Regeneron reach agreement over biosimilar dispute
(Image Credit: AdobeStock) Sandoz and Regeneron Pharmaceuticals have announced an agreement settling all patent disputes between the 2 companies relating to the US Food and Drug Administration (FDA)-approved Sandoz aflibercept biosimilar. Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv)…
Using OCT-A to explore biomarkers for neurodegenerative diseases
Amir H. Kashani, MD, PhD, a professor of ophthalmology at Johns Hopkins University, discussed a significant research publication in Alzheimers and Dementia that explored OCT-A angiography’s potential in studying neurodegenerative diseases. The study focused on developing a consensus method for…
UnitedHealthcare updates Glaucoma Surgical Treatments policy
(Image Credit: AdobeStock/gguy) UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to include goniotomy, trabeculotomy, canaloplasty (ab interno), combined canaloplasty (ab interno), and trabeculotomy procedures when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataracts…
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Positive topline data announced from AVONELLE-X and SALWEEN trials
(Image credit: ©pressmaster/AdobeStock) Roche recently announced new data from the AVONELLE-X and SALWEEN trials of Vabysmo (faricimab).1 These trial data were presented at the 25th European Society of Retina Specialists (EURETINA) Annual Congress held September 4-7 in Paris. Positive safety,…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
What if? Curing any eye disease with the snap of your finger
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Celltrion announces phase 3 trial data for EYDENZELT
(Image credit: ©HockleyM2) Celltrion recently announced 52-week findings from its global phase 3 clinical trial for its ophthalmic treatment candidate, EYDENZELT.1 EYDENZELT, a biosimilar of EYLEA (aflibercept), is Celltrion’s ophthalmic treatment candidate for the treatment of multiple retinal diseases, including…